Rapid and excessive rise of temperature accompanied by muscular rigidity following general anesthesia.
| Excerpt | Reference |
|---|
| "Malignant hyperthermia is a dominantly inherited, usually subclinical, disease that occurs in individuals who have an underlying muscular disorder and connotes the gravest possible consequences." | ( Bronstein, SL; Mahowald, MC; Ryan, DE; Solomons, CC, 1979) |
| "Malignant hyperpyrexia is a genetically related syndrome that cannot be predicted reliably in advance of administration of anesthesia except by a strong family history." | ( Stephen, CR, 1977) |
| "Malignant hyperthermia is an inherited muscular disorder and a cause of sudden death in afflicted patients." | ( Barak, AJ; Connolly, JF; Jardon, OM; Wingard, DW, 1979) |
| "Malignant hyperpyrexia is a dangerous complication of general anesthesia occurring in individuals with an underlying disease of muscle." | ( Denborough, MA, 1975) |
| "Malignant hyperthermia is a rare but severe complication of modern anesthesia, induced by halothane and succinylcholine." | ( Gullotta, F; Helpap, B, 1975) |
| "Realising that malignant hyperthermia is an inheritable disease, prophylactic measures such as, f." | ( Freiberger, K; Gullotta, F; Helpap, B; Menzel, H, 1976) |
| "Malignant hyperthermia is a genetic disease that may become apparent after exposure to drugs; some of these drugs are commonly used by the oral surgeon." | ( Gracia, RM; Schwartz, HC, 1975) |
| "Malignant hyperthermia is an autosomal dominant disorder occurring mainly with the administration of halogenated fluoroethane and depolarizing muscle relaxants." | ( Newell, FW, 1975) |
| "Malignant hyperthermia is induced by potent inhalation anesthetics." | ( Caropreso, PR; Gittleman, MA; Patterson, LT; Reilly, DJ, 1975) |
| "Malignant hyperpyrexia is a highly lethal complication of general anesthesia." | ( Bloom, DA; Fonkalsrud, EW; Reynolds, RC, 1976) |
| "Malignant hyperthermia is a potentially fatal disease that may be triggered by the administration of specific drugs or by stress." | ( Haas, DA; Harper, DG; Young, ER, 1992) |
| "Malignant hyperthermia is usually triggered by halogenated anesthetic agents with or without depolarizing muscle relaxants." | ( Edleman, KJ; Johnson, C, 1992) |
| "Malignant hyperthermia is a rare syndrome that occurs in genetically susceptible individuals who are exposed to frequently used inhalation anesthetics." | ( Moore, JL; Rice, EL, 1992) |
| "Malignant hyperthermia is caused by an abnormal increase in Ca2+ levels in skeletal muscle in response to anesthetics, including halothane." | ( Fletcher, JE; Mayerberger, S; Rosenberg, H; Tripolitis, L; Yudkowsky, M, 1991) |
| "Malignant hyperthermia is a potentially fatal pharmacogenetic disorder triggered by volatile anesthetics (halothane, enflurane, isoflurane) and/or succinylcholine." | ( Censier, K; Drewe, J; Frei, F; Rothenbühler, JM; Seeberger, MD; Urwyler, A, 1991) |
| "Although malignant hyperthermia is still a potentially fatal disease that was marked by a high mortality until recently, lasting damage to the patient can now be prevented by early diagnosis and treatment." | ( Hannemann, L; Kersting, T; Meier-Hellmann, A; Reinhart, K; Römer, M, 1990) |
| "The muscle disease malignant hyperthermia is a disorder of intracellular free Ca2+ regulation in both humans and pigs." | ( Heffron, JJ; McCarthy, TV, 1990) |
| "Malignant Hyperthermia is a specific potentially fatal condition which occurs in susceptible individuals in response to various triggering mechanisms, of which anesthetic agents have been found to be the most common offenders." | ( Hippius, H; Spiess-Kiefer, C, 1986) |
| "Malignant hyperthermia is a threat to the life of the surgical patient." | ( Manino, J; Turpin, IM, 1989) |
| "Malignant hyperthermia is a potentially lethal syndrome that can be triggered by inhaled anesthetics." | ( Beebe, JJ; Sessler, DI, 1988) |
| "Malignant hyperthermia is a seemingly rare genetic myopathy." | ( Abdul-Rasool, IH; Dubrow, TJ; Lesavoy, MA; Wackym, PA, 1988) |
| "Malignant hyperthermia is a hereditary trait characterized by hypercatabolic reactions induced by anesthetic drugs, or physical or emotional stress." | ( Britt, BA; Tomarken, JL, 1987) |
| "Malignant hyperthermia is a rare genetic abnormality which presents in the peri-anaesthetic period with tachycardia, hyperventilation, hyperthermia and acidosis." | ( Couper, JL; Lombard, TP, 1988) |
| "Malignant hyperthermia is a seemingly rare genetic myopathy." | ( Abdul-Rasool, IH; Dubrow, TJ; Peacock, WJ; Wackym, PA, 1988) |
| "Malignant hyperthermia is an inherited disease of skeletal muscle characterized by acute elevations of body temperature." | ( Allen, C; Johnstone, D; Landymore, RW; Wood, J, 1987) |
| "Malignant hyperthermia is one of the most devastating crises encountered in anaesthesia and it frequently occurs unexpectedly." | ( Popp, M; Seeling, W, 1986) |
| "Malignant hyperthermia is an often lethal hypermetabolic crisis state precipitated by a variety of pharmacological and environmental triggers in genetically susceptible persons." | ( Loghmanee, F; Tobak, M, 1986) |
| "Malignant hyperthermia is a muscle disease characterized by an abnormal response to anaesthetics, stress, and exercise." | ( Britt, BA; Elliott, ME; Klip, A; Pegg, W; Ramlal, T; Walker, D, 1986) |
| "Two cases of malignant hyperthermia are described where the earliest sign was a rise in the end-tidal CO2 concentration." | ( Baudendistel, L; Cote', C; Goudsouzian, N; Strafford, M, 1984) |
| "Malignant hyperthermia is a hypermetabolic, frequently fatal syndrome triggered by anesthetic drugs that occurs in genetically susceptible persons." | ( Adriani, J; Sundin, R, 1984) |
| "Malignant hyperthermia is a relatively newly defined problem that is associated with anesthesia." | ( Bloom, DA; Ehrlich, RM; Iwamoto, K; Reynolds, RC, 1981) |
| "Malignant hyperthermia is an autosomal dominant disorder with variable expressivity that is caused by a membrane defect in the sarcolemma of myofibrils." | ( Dodd, MJ; Phattiyakul, P; Silpasuvan, S, 1981) |
| "Malignant hyperthermia is a pharmacogenetic disease involving uninhibited flow of calcium ion into the muscle substance." | ( Waterman, PM, 1981) |
| "Malignant Hyperthermia is a life-threatening crisis frequently triggered by the use of various anesthetic agents." | ( Anderson, TE; Breed, AL; Drummond, DS; Taylor, CA, 1981) |
| "Malignant hyperthermia is a pharmacogenetic disorder of skeletal muscle that may cause a life-threatening reaction during administration of general anesthesia." | ( Allen, GC, 1993) |
| "Malignant hyperpyrexia is an inherited disorder of skeletal muscle characterized by intermittent hypermetabolic crises, usually triggered by anaesthetic agents." | ( Burns, AP; Hall, G; Hopkins, PM; Pusey, CD, 1993) |
| "Malignant hyperthermia is a seemingly rare genetic myopathy." | ( Blackwell, KE; Wackym, PA, 1994) |
| "Malignant hyperthermia is a complication of general anesthesia that is especially problematic if it occurs during renal transplantation because myoglobinemia, shock, and ischemia play a role in injuring the transplanted kidney." | ( Brennan, DC; Flye, MW; Goss, JA; Howard, TK; McClure, S; Miller, BT; Shenoy, S, 1996) |
| "Malignant hyperthermia is an inherited autosomal disorder of skeletal muscle in which certain volatile anesthetics and depolarizing muscle relaxants trigger an abnormally high release of Ca2+ from the intracellular Ca2+ store, the sarcoplasmic reticulum." | ( Deufel, T; Herrmann-Frank, A; Lehmann-Horn, F; Richter, M; Schleithoff, L, 1997) |
| "Human malignant hyperthermia is a heterogeneous disorder, and the down-regulation of SkM2 may be involved in the final common pathway through which mutations in any one of several proteins, including the ryanodine receptor, could render a person susceptible." | ( Beech, J; Fletcher, JE; Karan, SM; Rosenberg, H; Wieland, SJ, 1997) |
| "Malignant hyperthermia is a rare autosomal dominant trait that predisposes affected individuals to great danger when exposed to certain anaesthetic triggering agents (such as potent volatile anaesthetics and succinylcholine)." | ( Adnet, P; Ben Abraham, R; Glauber, V; Perel, A, 1998) |
| "Malignant hyperthermia is a main cause of death during general anesthesia, particularly in children." | ( File, SE; Gonzalez, LE; Gregson, NA; Meléndez-Vásquez, CV, 1998) |
| "Malignant hyperthermia is a rare complication in clinical anesthesia, especially associated with the administration of succinylcholine or inhalation anesthetics." | ( Chia, YY; Lee, MC; Liu, K; Liu, YC; Lo, Y, 1998) |
| "Malignant hyperthermia is a serious anesthetic complication, presenting with various manifestations, with high mortality and morbidity." | ( Bracco, D; Chastonay, P; Freymond, D; Ravussin, P, 1999) |
| "Malignant hyperthermia is an uncommon, heritable condition triggered by anesthesia and is followed by an increase in temperature that may be fatal without prompt treatment." | ( Brooks, AG; Castresana, MR; Lane, JE; Logan, MS; Newman, WH, 2000) |
| "Malignant hyperthermia is a pharmacogenetic disorder associated with mutations in Ca(2+) regulatory proteins." | ( Goldfarb, LG; Jankovic, J; Ji, J; Meissner, G; Mullakandov, M; Nelson, TE; Rosenberg, H; Sambuughin, N; Sivakumar, K; Xin, C, 2001) |
| "Malignant hyperthermia is an autosomal-dominant inherited disorder of the skeletal muscle cell characterized by a hypermetabolic response to all commonly used inhalational anaesthetics and depolarizing muscle relaxants." | ( Wappler, F, 2001) |
| "Susceptibility to malignant hyperthermia is diagnosed by contracture test, which requires an open muscle biopsy sample." | ( Anetseder, M; Hager, M; Müller, CR; Roewer, N, 2002) |
| "Malignant hyperthermia is a rare but potentially fatal metabolic syndrome triggered in susceptible patients by certain inhalational anesthetics and depolarizing muscle relaxants." | ( Haslego, SS, 2002) |
| "Malignant hyperthermia is a potentially fatal genetic myopathy that presents when the patient is under anesthesia." | ( Heggie, JE, 2002) |
| "Malignant hyperthermia is a potentially fatal pharmacogenetic disease triggered by volatile anesthetics and/or succinylcholine." | ( Ben Ammar, MS; Bouhajja, B; Haddad, F, 2002) |
| "Malignant hyperthermia is triggered by volatile anesthetics and succinylcholine." | ( Glahn, KP, 2003) |
| "Malignant hyperthermia is an autosomal dominant disorder of the skeletal muscle that predisposes affected individuals to a life-threatening hypermetabolic reaction in response to volatile anaesthetics and depolarizing muscle relaxants." | ( Kress, HG; Zeitlhofer, J; Zimprich, F, 2003) |
| "The diagnosis of malignant hyperthermia is currently performed with the in-vitro contracture test (IVCT) with halothane and caffeine." | ( Fiege, M; Gerbershagen, MU; Kolodzie, K; Schulte am Esch, J; Wappler, F; Weisshorn, R, 2004) |
| "Human malignant hyperthermia is a life-threatening genetic sensitivity of skeletal muscles to volatile anaesthetics and depolarizing neuromuscular blocking drugs occurring during or after anaesthesia." | ( Fiege, M; Gerbershagen, MU; Krause, T; Wappler, F; Weisshorn, R, 2004) |
| "Malignant hyperthermia is a rare and possibly life-threatening complication to anaesthesia." | ( Aasly, J; Haugen, T; Müller, CR; Toft, M, 2005) |
| "Malignant hyperthermia is an inherited disorder of skeletal muscle characterized by muscle contracture and hypermetabolic crisis following exposure to halogenated anaesthetics and depolarizing muscle relaxants." | ( Andria, B; Bracco, A; Cozzolino, S; Di Martino, A; Mancini, A; Savoia, G; Scala, D; Tammaro, A, 2006) |
| "Malignant hyperthermia is a pharmacogenetic disorder affecting humans, dogs, pigs, and horses." | ( Allen, PD; Esteve, E; Goth, S; Lopez, JR; Matthaei, KI; Pessah, IN; Riehl, J; Yang, T, 2006) |
| "Malignant hyperthermia is an uncommon complication encountered during the treatment of patients with diabetic ketoacidosis." | ( Baluch, AR; Oommen, SP, 2007) |
| "Malignant hyperthermia is a pharmacogenetic disease of skeletal muscle in which a life-threatening, hypermetabolic syndrome is induced by exposure of susceptible patients to halogenated general anaesthetics and/or succinylcholine." | ( Carmo, PL; Sudo, RT; Trachez, MM; Zapata-Sudo, G, 2008) |
| "Malignant hyperthermia is a rare anesthetic-related disorder." | ( Hsieh, AY; Hsu, SC; Huang, WT; Yeh, HM, 2007) |
| "Malignant hyperthermia is a pharmacogenetic disorder caused by autosomal dominant mutations in the ryanodine receptor type 1 gene." | ( Kawamoto, M; Kobayashi, M; Migita, T; Mukaida, K; Nishino, I; Yuget, O, 2007) |
| "Malignant hyperthermia is an autosomal dominant disorder with incomplete penetrance and variable expression." | ( Azevedo, DM; Coelho, GR; Fernandes, CR; Garcia, JH; Gomes, JM; Gonçalves, BP; Vasconcelos, JB, 2007) |
| "Malignant hyperthermia is a condition for which the anesthesiologist must be prepared to take specific measures." | ( Ortiz Gómez, JR, 2008) |
| "Malignant hyperthermia is a pharmacogenetic skeletal muscle disorder of intracellular calcium (Ca2+) homeostasis with an autosomal dominant inheritance." | ( Hamada, H; Kawamoto, M; Kobayashi, M; Migita, T; Mukaida, K; Nishino, I; Yuge, O, 2009) |
| "Malignant hyperthermia is a potentially lethal inherited hypermetabolic syndrome that develops in susceptible individuals following administration of depolarising neuromuscular relaxants or volatile anaesthetics." | ( Anetseder, M; Kranke, P; Metterlein, T; Roewer, N; Schuster, F, 2011) |
| "Malignant hyperthermia is a life-threatening condition caused by autosomal dominant mutations in the ryanodine receptor type 1 gene." | ( Hamada, H; Kawamoto, M; Kobayashi, M; Migita, T; Mukaida, K; Yuge, O, 2011) |
| "When malignant hyperthermia is diagnosed after induction of anesthesia, we found that with charcoal filters in place, the current anesthesia machine may be used for at least 67 minutes before the inspired concentration exceeds 5 ppm." | ( Birgenheier, N; Orr, J; Stoker, R; Westenskow, D, 2011) |
| "Malignant hyperthermia is a dreaded complication of general anaesthesia." | ( Hoppe, K; Jäger, H; Klingler, W; Lehmann-Horn, F; Schleip, R, 2014) |
| "Malignant hyperthermia is a pharmacogenetic disorder typically triggered by potent inhalation anesthetics and/or the depolarizing muscle relaxant succinylcholine in malignant hyperthermia-susceptible individuals." | ( Bina, S; Bünger, R; Capacchione, J; Muldoon, S; Munkhuu, B, 2015) |
| "Malignant hyperthermia is a life-threatening disorder caused by exposure to certain anesthetics." | ( Carpenter, V; LaRiccia, B; Papadakos, PJ, 2015) |
| "Malignant hyperthermia is a potentially fatal hypermetabolic disorder triggered by halogenated anesthetics and the myorelaxant succinylcholine in genetically predisposed individuals." | ( Alamelu, J; Brink, M; Byrne, S; Clement, E; Jungbluth, H; Lopez, RJ; Mohammed, S; Muntoni, F; Radunovic, A; Sekulic-Jablanovic, M; Snoeck, M; Treves, S; Voermans, N; Vukcevic, M; Wraige, E; Xu, L; Zhou, H; Zorzato, F, 2016) |
| "Malignant hyperthermia is a hypermetabolic syndrome that appears in susceptible patients after exposure to certain anaesthetic drugs (succinylcholine, inhalation anaesthetics)." | ( Alsina, E; Del Blanco, B; Domínguez, A; García, A; Guerrero, JL; Kollmann-Camaiora, A; Yepes, MJ, 2017) |
| "Malignant hyperthermia is a rare condition that occurs in susceptible patients exposed to triggering anesthetic agents." | ( Bonnick, AM; Fadahunsi, O; Gibbs, IC; Reid, N, 2019) |
| "Malignant hyperthermia is a well-known but potentially lethal disorder which is triggered by volatile anesthetics and depolarizing muscle relaxants." | ( Zhang, Y; Zhou, R, 2019) |
| "Malignant hyperthermia is a pharmacogenetic disorder, which is an uncommon but frequently fatal intricacy of inhalation anesthesia in man." | ( Cui, YF; Liu, XM; Sun, QC; Zhao, P, 2019) |
| "Malignant hyperthermia is a rare pharmacogenetic syndrome characterized by a severe hypermetabolic reaction after the administration of halogenated inhalational anesthetics or depolarizing muscle relaxants such as succinylcholine, or both." | ( Almeida, CG; Colleti Junior, J, 2020) |
| "Malignant hyperthermia is defined in the International Classification of Diseases as a progressive life-threatening hyperthermic reaction occurring during general anaesthesia." | ( Dalay, S; Girard, T; Hopkins, PM; Jenkins, B; McGrady, E; Patteril, M; Thacker, A, 2021) |
| "Malignant hyperthermia is triggered by not only anesthetic agents but also viral infections." | ( Chiba, N; Kinoshita, K; Matsuzaki, M; Mawatari, T; Mizuochi, M; Sakurai, A, 2021) |
| "Malignant hyperthermia is a rare but life-threatening pharmacogenetic muscle disorder characterized by abnormal hypermetabolic reactions and commonly triggered in susceptible individuals by volatile anesthetics or succinylcholine, or both." | ( Gong, X, 2021) |
| "Malignant hyperthermia is a life-threatening disorder, which can be prevented by avoiding certain anesthetic agents." | ( De Bleecker, JL; De Puydt, J; Herdewyn, S; Janssens, L; Milazzo, M; Symoens, S, 2022) |
| "Malignant hyperthermia is an extremely dangerous condition that can occur with exposure to volatile inhalant anesthetics and depolarizing muscle relaxants, and that requires immediate intervention." | ( Ikeda, A; Kajihama, A; Minami, S; Nagafuchi, H; Shimizu, H; Yamada, K, 2023) |
| Excerpt | Reference |
|---|
| "Two patients with successfully treated malignant hyperpyrexia are reported." | ( Liebenschütz, F; Mai, C; Pickerodt, VW, 1979) |
| "We describe a development of a malignant hyperthermia (MH) syndrome, partially aborted by therapy, in a child with central core disease and congenital dislocating hips." | ( Eng, GD; Engel, WK; Epstein, BS; McKay, DW; McKay, R, 1978) |
| "We encountered a case of malignant hyperthermia caused by intravenous lidocaine which had been administered as treatment for a ventricular arrhythmia." | ( Ida, K; Inoue, M; Katoh, S; Kondoh, M; Okuda, J; Tatsukawa, H; Terashima, S, 1992) |
| "These episodes were not considered to be malignant hyperthermia and were not treated with dantrolene." | ( Hartley, EJ; Levine, MF; Yentis, SM, 1992) |
| "Although malignant hyperthermia is still a potentially fatal disease that was marked by a high mortality until recently, lasting damage to the patient can now be prevented by early diagnosis and treatment." | ( Hannemann, L; Kersting, T; Meier-Hellmann, A; Reinhart, K; Römer, M, 1990) |
| "Though a malignant hyperthermia (MH) crisis is still a critical event during general anesthesia, recent developments in prophylaxis and treatment should help in avoiding fatal episodes." | ( Klein, W; Küther, G; Lehmann-Horn, F; Pongratz, D; Spiess-Kiefer, C, 1987) |
| "There was no evidence of malignant hyperthermia (MH) in patients receiving succinylcholine, suggesting that an association between NMS and MH may not be clinically relevant in patients being treated with ECT." | ( Addonizio, G; Susman, VL, 1987) |
| "Where malignant hyperthermia has developed patients have been successfully treated with further dantrolene therapy." | ( Chaffman, MO; Sorkin, EM; Ward, A, 1986) |
| "Pietrain pigs susceptible to malignant hyperthermia (MH; porcine stress syndrome) were treated with the slow-channel calcium blocker verapamil and then subjected to halothane testing." | ( Lee, JC; McGrath, CJ; Rempel, WE, 1984) |
| "If unrecognized and/or untreated, malignant hyperthermia can be fatal." | ( Kindred, D; Young, MS, 1993) |
| "He was treated for malignant hyperthermia." | ( Hopkins, D; Shipton, EA, 1993) |
| "Dantrolene effectively treats malignant hyperthermia (MH) hut the current form, Dantrium, must be dissolved to a 0." | ( Bina, S; Boedeker, BH; Haynes, DH; Karan, SM; Lojeski, EW; Muldoon, SM; Wesche, DL, 1996) |
| "In this report, we describe a case of malignant hyperthermia, its clinical course, and the measures taken to successfully treat it and preserve the function of a kidney allograft." | ( Brennan, DC; Flye, MW; Goss, JA; Howard, TK; McClure, S; Miller, BT; Shenoy, S, 1996) |
| "Because malignant hyperthermia (MH) was suspected, he was treated with dantrolene, fluid loading, and continuous hemodiafiltration along with symptomatic supportive care." | ( Akazawa, H; Hirai, H; Hoshide, S; Hosoya, N; Kanda, Y; Maekawa, K; Mimura, T; Miyagawa, K; Takahashi, N; Yazaki, Y, 1997) |
| "A case of suspected malignant hyperthermia in a 13-month-old female, to whom succinylcholine was not administered, is presented." | ( Carvill, KA; Eckert, T; Smith, CA, 1997) |
| "Dantrolene is used to treat malignant hyperthermia (MH), a genetic predisposition to excessive intracellular Ca2+ release upon exposure to volatile anaesthetics." | ( Louis, CF; Mickelson, JR; Palnitkar, SS; Parness, J, 1997) |
| "Porcine malignant hyperthermia (MH) can be triggered by administration of certain serotonin2 receptor agonists." | ( Fiege, M; Köchling, A; Lambrecht, W; Scholz, J; Schulte am Esch, J; von Richthofen, V; Wappler, F, 1997) |
| "When malignant hyperthermia-does occur in the operating room, prompt recognition and treatment usually prevent a potentially fatal outcome." | ( Adnet, P; Ben Abraham, R; Glauber, V; Perel, A, 1998) |
| "The delayed onset of malignant hyperthermia after delivery of halothane is unusual and for successful treatment careful monitoring and rapid and aggressive therapy are needed." | ( Brodbelt, DC; Taylor, PM, 1998) |
| "Episodes of malignant hyperthermia were not triggered in response to administration of low doses of 4-chloro-m-cresol, but transient cardiovascular reactions (e." | ( Gallagher, WJ; Iaizzo, PA; Johnson, BA; Nagao, K, 1999) |
| "All MHS swine developed malignant hyperthermia after administration of 4-CmC in doses of 12 or 24 mg/kg." | ( Fiege, M; Kolodzie, K; Kudlik, C; Scholz, J; Schulte am Esch, J; Wappler, F; Weisshorn, R, 1999) |
| "In this article the pathophysiology of malignant hyperthermia, its signs, symptoms and treatment as well as safe anesthetic agents for individuals susceptible to malignant hyperthermia are discussed." | ( Glahn, KP, 2003) |
| "We suspected atypical malignant hyperthermia and began its treatment." | ( Akashi, Y; Sato, M; Sato, R; Suzuki, H; Tanito, Y, 2006) |
| "We describe a case of malignant hyperthermia encountered and treated during surgical operations concurrent with an overseas humanitarian assistance mission." | ( Blaschke, G; Jones, S; Pfeiffer, J; Plurad, D, 2008) |
| "We analyzed cases of malignant hyperthermia (MH) reported to the North American MH Registry for clinical characteristics, treatment, and complications." | ( Allen, GC; Brandom, BW; Gronert, GA; Larach, MG; Lehman, EB, 2010) |
| "In all malignant hyperthermia susceptible animals, the inhaled administration of halothane 0." | ( Becker, S; Burmester, S; Gerbershagen, MU; Kröner, L; Lenz, D; Schütte, JK; Starosse, A; Wappler, F, 2011) |
| "After achieving predefined malignant hyperthermia criteria, standardised therapy was initiated; dantrolene sodium suspension (5 mg kg(-1)) was administered and the injection was repeated after 24 min." | ( Becker, S; Gerbershagen, MU; Oldewurtel, C; Richard, A; Schäfer, U; Schütte, JK; Singler, P; Starosse, A; Wappler, F, 2013) |
| "The clinical symptoms resemble malignant hyperthermia (MH), which may lead to mistreatment of the patient." | ( Adolph, O; Chaiklieng, S; Hoppe, K; Jurkat-Rott, K; Klingler, W; Lehmann-Horn, F, 2013) |
| "Dantrolene is the first line therapy of malignant hyperthermia." | ( Gomez-Hurtado, N; Imtiaz, MS; Knollmann, BC; Laver, DR; Oo, YW; van Helden, DF; Walweel, K, 2015) |
| "There are no case reports of malignant hyperthermia in pediatric patients treated on cardiopulmonary bypass (CPB)." | ( Kuntz, MT; Saab, AD, 2019) |
| "Although dantrolene effectively treats malignant hyperthermia (MH), discrepant recommendations exist concerning dantrolene availability." | ( Adelman, BT; Aziz, MF; Belani, KG; Berman, MF; Berris, J; Biggs, DA; Brandom, BW; Capacchione, J; Coffman, T; Coles, P; Craft, RM; Cummings, KC; Durieux, ME; Ellis, TA; Ginde, AA; Harris, JM; Helsten, DL; Herlich, A; Kheterpal, S; Kim, TW; Klumpner, TT; Kooij, F; LaGorio, J; Larach, MG; Limoncelli, J; Lins, S; Mackey, SC; Mashman, D; McCormick, PJ; Miller, SA; Molina, S; Nair, BJ; Nanamori, M; Neuman, MD; Pace, NL; Paganelli, WC; Peterson, W; Price, Z; Riazi, S; Schonberger, RB; Sivak, EL; Soto, R; Tom, S; Turnbull, ZA; van Klei, WA; Vaughn, MT; Wanderer, JP; Wedeven, C; Wilczak, J, 2019) |
| "With a diagnostic hypothesis of malignant hyperthermia, dantrolene was then administered, which immediately induced muscle stiffness, tachycardia, tachypnea and reduced body temperature." | ( Almeida, CG; Colleti Junior, J, 2020) |